Lead Product(s) : Vecabrutinib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sunesis Pharmaceuticals Announces Clinical Update on Vecabrutinib Program
Details : Company will not advance its non-covalent BTK inhibitor vecabrutinib into the planned Phase 2 portion of the Phase 1b/2 trial in adults with relapsed/refractory chronic lymphocytic leukemia and other B-cell malignancies.
Product Name : SNS-062
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 23, 2020
Lead Product(s) : Vecabrutinib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable